Transdermal GFR Measurement
Client
MediBeacon
Practice Areas
Challenge
MediBeacon required expert assistance to develop a photonics-based transdermal detection technology to monitor intravenously injected fluorescent tracer agents and provide clinically actionable measures of kidney function. MediBeacon has brought combination products into the clinic which match fluorescent tracers with innovative detection systems to provide accurate physiological measurements in real-time. Triple Ring, in collaboration with MediBeacon, designed and delivered a non-invasive, light-based wearable detection system as a critical component of their glomerular filtration rate (GFR) monitoring product. The detectors were designed and developed to meet strict product requirements of sensitivity, accuracy, cost, comfort, and ease of use.
Outcomes
Fully integrated wearable GFR detectors were developed under ISO13485 design controls and delivered for critical clinical trials.
Triple Ring Value Proposition
- Highly relevant expertise in light-based tissue analysis
- Advanced modeling and simulations to speed design process
- Program structure that included skin in the game
- Deep experience in meeting critical milestones for venture funding
Transdermal GFR Measurement
Challenge
MediBeacon required expert assistance to develop a photonics-based transdermal detection technology to monitor intravenously injected fluorescent tracer agents and provide clinically actionable measures of kidney function. MediBeacon has brought combination products into the clinic which match fluorescent tracers with innovative detection systems to provide accurate physiological measurements in real-time. Triple Ring, in collaboration with MediBeacon, designed and delivered a non-invasive, light-based wearable detection system as a critical component of their glomerular filtration rate (GFR) monitoring product. The detectors were designed and developed to meet strict product requirements of sensitivity, accuracy, cost, comfort, and ease of use.
Outcomes
Fully integrated wearable GFR detectors were developed under ISO13485 design controls and delivered for critical clinical trials.
Triple Ring Value Proposition
- Highly relevant expertise in light-based tissue analysis
- Advanced modeling and simulations to speed design process
- Program structure that included skin in the game
- Deep experience in meeting critical milestones for venture funding
Client
MediBeacon
Practice Areas
Background
MediBeacon selected Triple Ring as their development partner for our multidisciplinary science and engineering teams. Triple Ring’s industry leading capabilities in biophotonics and combination product development, along with our ability to collaborate closely and share risk, made us an optimal partner for MediBeacon.
Microneedle Patch Applicator
Client
Confidential
Practice Areas
Challenge
The client had developed a novel microneedle patch for transdermal drug delivery intended for use by the patient at home. The patch required a significantly greater degree of uniformity in pressure during application than existing transdermal patches. It required design of a reusable applicator to achieve reliable adhesion and dosing, while supporting the robustness and ruggedness requirements for use by a patient in their home and a low cost.
The key was ensuring that the patch would work across a wide variety of skin types in the potential patient population. Triple Ring relied on its expertise in material design and selection, precision mechanical engineering, and our life scientists to design an applicator that provided the required pressure for patch adhesion, across skin types that varied by thickness, age, moisture content, and placement.
Outcomes
The resulting single-entity combination product comprised a reusable applicator and a microneedle array containing patch, for intracutaneous drug delivery allowing rapid absorption into the bloodstream. With the applicator, the client was able to successfully enter clinical trials. Ultimately the technology for the product was acquired by a vaccine manufacturer.
Value Propositions
Triple Ring’s interdisciplinary team had all the required skills for a complex design.
Microneedle Patch Applicator
Challenge
The client had developed a novel microneedle patch for transdermal drug delivery intended for use by the patient at home. The patch required a significantly greater degree of uniformity in pressure during application than existing transdermal patches. It required design of a reusable applicator to achieve reliable adhesion and dosing, while supporting the robustness and ruggedness requirements for use by a patient in their home and a low cost.
The key was ensuring that the patch would work across a wide variety of skin types in the potential patient population. Triple Ring relied on its expertise in material design and selection, precision mechanical engineering, and our life scientists to design an applicator that provided the required pressure for patch adhesion, across skin types that varied by thickness, age, moisture content, and placement.
Outcomes
The resulting single-entity combination product comprised a reusable applicator and a microneedle array containing patch, for intracutaneous drug delivery allowing rapid absorption into the bloodstream. With the applicator, the client was able to successfully enter clinical trials. Ultimately the technology for the product was acquired by a vaccine manufacturer.
Value Propositions
Triple Ring’s interdisciplinary team had all the required skills for a complex design.
Client
Confidential
Practice Areas
Background
The client was a publicly traded company with deep medical and domain expertise to address a drug delivery problem using their novel patch technology. They selected Triple Ring to design the mechanical delivery device based upon our long history of working with designing novel technologies for health care that delivered excellent user experiences. The Triple Ring designed applicator allowed the client to both more easily demonstrate their technology to other health care professionals and to get it into the hands of end users in clinical trials.
